HU227332B1 - Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation - Google Patents

Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation Download PDF

Info

Publication number
HU227332B1
HU227332B1 HU0203277A HUP0203277A HU227332B1 HU 227332 B1 HU227332 B1 HU 227332B1 HU 0203277 A HU0203277 A HU 0203277A HU P0203277 A HUP0203277 A HU P0203277A HU 227332 B1 HU227332 B1 HU 227332B1
Authority
HU
Hungary
Prior art keywords
use according
threosulfan
surface area
body surface
cyclophosphamide
Prior art date
Application number
HU0203277A
Other languages
English (en)
Hungarian (hu)
Inventor
Joachim Baumgart
Original Assignee
Medac Klinische Spezialpraep
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medac Klinische Spezialpraep filed Critical Medac Klinische Spezialpraep
Publication of HUP0203277A2 publication Critical patent/HUP0203277A2/hu
Publication of HU227332B1 publication Critical patent/HU227332B1/hu
Priority to HUS1900041 priority Critical patent/HUS1900041I1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
HU0203277A 1999-11-05 2000-11-03 Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation HU227332B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HUS1900041 HUS1900041I1 (hu) 1999-11-05 2019-09-18 Treoszulfán alkalmazása betegek csontvelõ- és vér õssejt-transzplantáció elõtti kondicionálására

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19953517A DE19953517C1 (de) 1999-11-05 1999-11-05 Verwendung von Treosulfan zur Konditionierung von Patienten vor Knochemarktransplantation oder Blutstammzelltransplantation
PCT/EP2000/010871 WO2001032154A2 (de) 1999-11-05 2000-11-03 Verwendung von treosulfan zur konditionierung von patienten vor knochenmarktransplantation oder blutstammzelltransplantation

Publications (2)

Publication Number Publication Date
HUP0203277A2 HUP0203277A2 (en) 2003-01-28
HU227332B1 true HU227332B1 (en) 2011-03-28

Family

ID=7928187

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0203277A HU227332B1 (en) 1999-11-05 2000-11-03 Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation
HUS1900041 HUS1900041I1 (hu) 1999-11-05 2019-09-18 Treoszulfán alkalmazása betegek csontvelõ- és vér õssejt-transzplantáció elõtti kondicionálására

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS1900041 HUS1900041I1 (hu) 1999-11-05 2019-09-18 Treoszulfán alkalmazása betegek csontvelõ- és vér õssejt-transzplantáció elõtti kondicionálására

Country Status (16)

Country Link
US (1) US7199162B1 (cg-RX-API-DMAC7.html)
EP (1) EP1227808B1 (cg-RX-API-DMAC7.html)
JP (1) JP4846151B2 (cg-RX-API-DMAC7.html)
AT (1) ATE251455T1 (cg-RX-API-DMAC7.html)
AU (1) AU777527B2 (cg-RX-API-DMAC7.html)
BG (1) BG65845B1 (cg-RX-API-DMAC7.html)
CA (1) CA2389896C (cg-RX-API-DMAC7.html)
CZ (1) CZ299701B6 (cg-RX-API-DMAC7.html)
DE (2) DE19953517C1 (cg-RX-API-DMAC7.html)
EA (1) EA004543B1 (cg-RX-API-DMAC7.html)
ES (1) ES2208435T3 (cg-RX-API-DMAC7.html)
HU (2) HU227332B1 (cg-RX-API-DMAC7.html)
NO (2) NO329616B1 (cg-RX-API-DMAC7.html)
PL (1) PL212132B1 (cg-RX-API-DMAC7.html)
UA (1) UA73961C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001032154A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
JP7431815B2 (ja) * 2018-09-26 2024-02-15 メダック ゲゼルシャフト フィア クリニッシェ スペツィアルプレパラーテ ミット ベシュレンクタ ハフトゥンク トレオスルファンの結晶形
PT4257122T (pt) 2018-09-26 2026-06-08 Medac Ges Fr Klinische Spezialprparate Mbh Liofilizado de treossulfano
EP3856252A1 (en) 2018-09-26 2021-08-04 medac Gesellschaft für klinische Spezialpräparate mbH Solution comprising treosulfan

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376546A (en) * 1991-11-04 1994-12-27 Xoma Corporation Analogs of ribosome-inactivating proteins
DE4421391C1 (de) * 1994-06-18 1995-11-30 Gsf Forschungszentrum Umwelt Verwendung von Antikörpern gegen T-Zellen zur verlängerten Immunsuppression
WO2000045842A2 (en) * 1999-02-04 2000-08-10 The General Hospital Corporation Methods for human allografting

Also Published As

Publication number Publication date
CA2389896A1 (en) 2001-05-10
ATE251455T1 (de) 2003-10-15
CZ20021562A3 (cs) 2002-10-16
BG65845B1 (bg) 2010-03-31
EP1227808B1 (de) 2003-10-08
NO2019032I1 (no) 2019-07-23
DE50004024D1 (de) 2003-11-13
EP1227808A2 (de) 2002-08-07
CZ299701B6 (cs) 2008-10-22
AU1391801A (en) 2001-05-14
WO2001032154A2 (de) 2001-05-10
DE19953517C1 (de) 2001-08-09
NO20022109L (no) 2002-07-01
US7199162B1 (en) 2007-04-03
PL212132B1 (pl) 2012-08-31
NO329616B1 (no) 2010-11-22
ES2208435T3 (es) 2004-06-16
EA004543B1 (ru) 2004-06-24
AU777527B2 (en) 2004-10-21
HUP0203277A2 (en) 2003-01-28
PL356240A1 (en) 2004-06-28
BG106772A (bg) 2003-02-28
NO20022109D0 (no) 2002-05-02
CA2389896C (en) 2007-04-10
UA73961C2 (uk) 2005-10-17
WO2001032154A3 (de) 2002-01-24
JP2003513034A (ja) 2003-04-08
JP4846151B2 (ja) 2011-12-28
EA200200535A1 (ru) 2002-10-31
HUS1900041I1 (hu) 2019-10-28

Similar Documents

Publication Publication Date Title
Endo et al. Underlying mechanisms and therapeutic strategies for bisphosphonate-related osteonecrosis of the jaw (BRONJ)
JP6918724B2 (ja) 急性骨髄性白血病(aml)のための新規併用治療
ES2214753T3 (es) Uso de 9-desoxi-2',9-alfa-metano-3-oxa-4,5,6-trinor-3,7-(1',3'-interfenilen)-13,14-dihidro-prostaglandina f1 para tratar la enfermedad vascular periferica.
US8034808B2 (en) Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine
DE68912331T2 (de) Erniedrigung der zellvermehrung und steigerung der killerzellenaktivität.
US6586428B2 (en) Combined preparations comprising morpholine anthracyclines and anticancer agent
Santini Amifostine: chemotherapeutic and radiotherapeutic protective effects
EA006598B1 (ru) Композиция, содержащая трамадол и противосудорожное лекарственное средство
HUP0200100A2 (hu) Eljárások és készítmények a fehérvérsejtek számának fokozására
Ludwig et al. Supportive care in multiple myeloma
JPH04505760A (ja) Aztの副作用および毒性からの保護方法
MXPA06002489A (es) Formulaciones anti-tumorales que contienen defibrotido solo o en combinacion con otros agentes anti-tumorales.
KR101458233B1 (ko) 백혈병을 치료하기 위한 신규한 치료 용도
US7199162B1 (en) Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.
HUP0102873A2 (hu) Bisz-foszfonsavakat és származékaikat tartalmazó gyógyszerkészítmények autoimmun betegségek és allergiák megelőzésére és kezelésére
IE851597L (en) Peroxydiphosphoric acid in tumor inhibition
EP1200099B1 (en) Synergistic composition comprising daunorubicin derivatives and antimetabolite compounds
JPH0753388A (ja) 骨代謝改善剤
JPWO2002092096A1 (ja) 抗腫瘍剤
DE2314387A1 (de) Arzneimittel zur behandlung boesartiger neubildungen, vorzugsweise von haemoblastosen und chorionepitheliom
Veys et al. Recombinant interferon gamma in rheumatoid arthritis. A double-blind study comparing Immuneron (recombinant interferon gamma) with placebo
US5861384A (en) Immunosuppressive-activity potentiating compositions
JPH02235813A (ja) 抗腫瘍剤
JP2003512331A (ja) 骨障害治療用アミノアルキレンホスホネート

Legal Events

Date Code Title Description
AA1S Information on application for a supplementary protection certificate

Spc suppl protection certif: S1900041

Filing date: 20190918

Expiry date: 20201103

HC9A Change of name, address

Owner name: MEDAC GESELLSCHAFT FUER KLINISCHE SPEZIALPRAEPA, D

Free format text: FORMER OWNER(S): MEDAC GESELLSCHAFT FUER KLINISCHE SPEZIALPRAEPARATE MBH., DE